Global Community

When investors look at the Malaysian construction and property sectors, giants like MRCB or Berjaya Corporation often dominate the conversation. However, peering into the micro-cap space often reveals hidden value.Read more

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more

NCT Alliance Berhad (“NCT”) has entered a new phase in its corporate journey with the appointment of Mr Ong Chou Wen as Chief Executive Officer, effective 1 April 2026. The leadership change comes at a meaningful juncture for the property developer, as the market continues to reward companies that can combine project execution, balance sheet discipline, and sharper commercial positioning in an increasingly competitive operating environment.Read more

Rating: Speculative Buy / High Risk Style: AI infrastructure “picks-and-shovels” growth name Core debate: Is AAOI a genuine bottleneck asset in AI networking, or a cyclical optics supplier temporarily enjoying peak demand and peak multiples? Executive view Applied Optoelectronics is no longer just a small-cap optical component company.Read more

When fuel costs stay high or become more volatile, the effect usually goes beyond just higher transport bills. Over time, it also pushes households, businesses and property owners to look more seriously at alternatives that can reduce long-term operating costs.Read more

Rating: Buy / Quality Compounder with Cyclical Entry Risk Style: Infrastructure-led industrial compounder Core debate: Is Prysmian still “just a cable manufacturer,” or has it become a scarce, strategic infrastructure platform leveraged to electrification, grid bottlenecks, and AI-era connectivity? Executive view Prysmian is one of the highest-quality ways to invest in the physical backbone of electrification and digitalization.Read more

Key Assumptions Metal Prices: Gold at $4,500/oz (80% above ~$2,500/oz) and silver at $100/oz (233% above ~$30/oz), held constant for simplicity. Real Inflation Rate: 8% annually, increasing operating costs (e.g., all-in sustaining costs, AISC) and potentially compressing valuation multiples.Read more